OM
TARA icon

Opaleye Management’s Protara Therapeutics TARA Stock Holding History

Opaleye Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-855,000
Closed -$2.59M – 50
2025
Q2 		$2.59M Sell
855,000
-875,000
-51% -$3.02M 0.52% 31
2025
Q1 		$7.37M Sell
1,730,000
-95,000
-5% -$424K 1.64% 12
2024
Q4 		$9.64M Buy
1,825,000
+143,846
+9% +$465K 1.69% 13
2024
Q3 		$3.08M Sell
1,681,154
-623,108
-27% -$1.28M 0.51% 31
2024
Q2 		$5.3M Sell
2,304,262
-388,332
-14% -$1.14M 1.21% 26
2024
Q1 		$10.8M Hold
2,692,594
– – 2.35% 14
2023
Q4 		$5.05M Hold
2,692,594
– – 1.34% 21
2023
Q3 		$4.5M Hold
2,692,594
– – 1.46% 18
2023
Q2 		$6.44M Hold
2,692,594
– – 1.54% 16
2023
Q1 		$8.08M Hold
2,692,594
– – 2.42% 10
2022
Q4 		$7.22M Sell
2,692,594
-15,473
-0.6% -$48.8K 2.51% 11
2022
Q3 		$7.99M Buy
2,708,067
+23,900
+0.9% +$81K 3.3% 8
2022
Q2 		$8.88M Buy
2,684,167
+10,136
+0.4% +$37.1K 4% 7
2022
Q1 		$13.7M Buy
2,674,031
+24,031
+0.9% +$126K 4.24% 8
2021
Q4 		$18M Buy
2,650,000
+91,528
+4% +$631K 3.82% 8
2021
Q3 		$17.7M Hold
2,558,472
– – 3.31% 9
2021
Q2 		$24.9M Hold
2,558,472
– – 4.14% 8
2021
Q1 		$40.3M Hold
2,558,472
– – 5.92% 3
2020
Q4 		$61.9M Hold
2,558,472
– – 8.09% 2
2020
Q3 		$43.1M Buy
2,558,472
+350,000
+16% +$8.12M 8.42% 2
2020
Q2 		$64.8M Hold
2,208,472
– – 13.08% 1
2020
Q1 		$52.1M Buy
2,208,472
+2,203,768
+46,849% +$64.2M 13.82% 1
2019
Q4 		$75K Buy
4,704
+3,354
+248% +$38.5K 0.01% 46
2019
Q3 		$14K Buy
+1,350
New +$19.3K 0.01% 49

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Opaleye Management's TARA Position: Q3 2025 in Review

Opaleye Management sold out of Protara Therapeutics (TARA) in Q3 2025, closing a stake of 855,000 shares — an estimated $2.59M sold.

Opaleye Management first reported a position in TARA in Q3 2019 and held it in 24 quarters. The position peaked at $64.8M in Q2 2020. 81 funds tracked by Wall St. Rank hold TARA as of Q3 2025.

  • Opaleye Management reported no remaining Protara Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Opaleye Management sold 855,000 Protara Therapeutics shares in Q3 2025, an estimated $2.59M.
  • Opaleye Management first reported a position in Protara Therapeutics in Q3 2019 and held it in 24 quarters.
  • Opaleye Management's Protara Therapeutics position peaked at $64.8M in Q2 2020.
  • 81 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2025.

Based on Opaleye Management's 13F filing for Q3 2025, filed 14 Nov 2025.